脑深部电刺激硬件相关感染:单中心10年经验
该单中心回顾性队列研究纳入2005年12月至2015年9月接受初次脑深部电刺激植入的242例成人共245次手术、464根电极,分析手术部位感染危险因素及预防性万古霉素粉末(VP)的效果。245次手术中90天内感染9例(3.7%),1年内16例(6.5%)。使用万古霉素粉末者感染率3.3%,未使用者9.7%(OR 0.32,95%CI 0.10-1.02,P=0.04);控制性别后未达预设显著性水平(校正OR 0.32,95%CI 0.10-1.03,P=0.06)。
要点
- 245次初次脑深部电刺激植入手术中,90天内手术部位感染9例(3.7%),1年内16例(6.5%)。
- 使用万古霉素粉末者感染率3.3%,未使用者9.7%(OR 0.32,95%CI 0.10-1.02,P=0.04)。
- 控制性别后万古霉素粉末与感染风险降低的关联未达预设显著性水平(校正OR 0.32,95%CI 0.10-1.03,P=0.06)。
核心结论
- 本研究中多数患者相关和手术相关因素与手术部位感染风险无关,数据提示万古霉素粉末可能有助于降低脑深部电刺激植入术后手术部位感染风险。
- 鉴于脑深部电刺激术后感染的影响及植入90天后仍频发感染,术后继续随访至少1年以确定真实感染负担并及时治疗是审慎的。
研究设计与样本
- 单中心回顾性队列研究,纳入2005年12月至2015年9月接受初次脑深部电刺激植入的成人患者,共242例、245次手术、464根电极,约10.5年。
- 评估围手术期(术前、术中、术后)预防性抗生素对手术部位感染率的影响,并分析美国国家医疗安全网络手术部位感染定义变更对感染检出的影响。
- 统计分析采用两样本t检验、Wilcoxon秩和检验、卡方检验、Fisher精确检验或logistic回归。
主要发现
- 245次手术中,90天内发生手术部位感染9例(3.7%),1年内16例(6.5%);革兰阳性菌为最常见病原体。
- 使用万古霉素粉末者手术部位感染率3.3%,未使用者9.7%(OR 0.32,95%CI 0.10-1.02,P=0.04)。
- 控制患者性别后,万古霉素粉末与手术部位感染风险降低的关联未达预设显著性水平(校正OR 0.32,95%CI 0.10-1.03,P=0.06)。
- 分期与未分期植入的手术部位感染率相似。
- 多数患者相关和手术相关特征在发生与未发生手术部位感染的患者间无差异。
临床怎么用
- 作者认为万古霉素粉末可能有助于降低脑深部电刺激植入术后手术部位感染风险。
- 作者认为脑深部电刺激术后继续随访至少1年以确定真实感染负担并及时治疗是审慎的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Deep brain stimulation is an effective surgical treatment for managing some neurological and psychiatric disorders. Infection related to the deep brain stimulator (DBS) hardware causes significant morbidity: hardware explantation may be required; initial disease symptoms such as tremor, rigidity, and bradykinesia may recur; and the medication requirements for adequate disease management may increase. These morbidities are of particular concern given that published DBS-related infection rates have been as high as 23%. To date, however, the key risk factors for and the potential preventive measures against these infections remain largely uncharacterized. In this study, the authors endeavored to identify possible risk factors for DBS-related infection and analyze the efficacy of prophylactic intrawound vancomycin powder (VP). METHODS: The authors performed a retrospective cohort study of patients who had undergone primary DBS implantation at a single institution in the period from December 2005 through September 2015 to identify possible risk factors for surgical site infection (SSI) and to assess the impact of perioperative (before, during, and after surgery) prophylactic antibiotics on the SSI rate. They also evaluated the effect of a change in the National Healthcare Safety Network's definition of SSI on the number of infections detected. Statistical analyses were performed using the 2-sample t-test, the Wilcoxon rank-sum test, the chi-square test, Fisher's exact test, or logistic regression, as appropriate for the variables examined. RESULTS: Four hundred sixty-four electrodes were placed in 242 adults during 245 primary procedures over approximately 10.5 years; most patients underwent bilateral electrode implantation. Among the 245 procedures, 9 SSIs (3.7%) occurred within 90 days and 16 (6.5%) occurred within 1 year of DBS placement. Gram-positive bacteria were the most common etiological agents. Most patient- and procedure-related characteristics did not differ between those who had acquired an SSI and those who had not. The rate of SSIs among patients who had received intrawound VP was only 3.3% compared with 9.7% among those who had not received topical VP (OR 0.32, 95% CI 0.10-1.02, p = 0.04). After controlling for patient sex, the association between VP and decreased SSI risk did not reach the predetermined level of significance (adjusted OR 0.32, 95% CI 0.10-1.03, p = 0.06). The SSI rates were similar after staged and unstaged implantations. CONCLUSIONS: While most patient-related and procedure-related factors assessed in this study were not associated with the risk for an SSI, the data did suggest that intrawound VP may help to reduce the SSI risk after DBS implantation. Furthermore, given the implications of SSI after DBS surgery and the frequency of infections occurring more than 90 days after implantation, continued follow-up for at least 1 year after such a procedure is prudent to establish the true burden of these infections and to properly treat them when they do occur.
引用
- Abode-Iyamah KO, Chiang HY, Woodroffe RW, et al. Deep brain stimulation hardware-related infections: 10-year experience at a single institution. J Neurosurg. 2018. PMID: 29521584. doi:10.3171/2017.9.JNS1780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。